| I-55 Angelica Quartino Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Wednesday 10:30-12:00 |
| I-55 Angelica Quartino Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Wednesday 10:30-12:00 |